PSMB5 and plasma cell myeloma: Bortezomib-resistance in myeloma occurs either due to up-regulation of HSF1 activity or due to altered redox homeostasis [29] or, in rare cases, due to accumulation of mutations in key bortezomib-docking sites in proteasome subunit of PSMB5 [8].